Wedbush Maintains Neutral on Abivax, Raises Price Target to $110
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains Abivax (NASDAQ:ABVX) with a Neutral and raises the price target from $90 to $110.
Wedbush analyst David Nierengarten maintains Abivax (NASDAQ:ABVX) with a Neutral and raises the price target from $90 to $110.